ASA Bans Four Adverts Promoting Prescription Weight Loss Pills
Four advertisements promoting prescription-only oral weight loss treatments have been banned by the Advertising Standards Authority (ASA), with two of the banned adverts coming from the provider Voy. The regulatory crackdown targets marketing across buses, video-on-demand services, and social media platforms that attempted to advertise restricted medical products to the general public.
The first GLP-1 tablet for weight loss was licensed to be sold as a medicine available only via prescription in June. Under UK regulations, prescription-only medicines cannot be advertised to the public. The ASA determined that Voy’s advertisements—including a July bus placement featuring a hand holding a white pill alongside the headline “The weight is over… Voy” and an August video-on-demand ad stating “Oral weight support”—were likely to lead people to understand they were advertising the newly available oral Wegovy tablets rather than an ordinary food supplement.
Small-Print Supplement Disclaimers Fail Regulator Test
Both banned ads from Voy included small-print references to glucomannan, a food supplement. However, the watchdog concluded that minor disclaimers were insufficient to alter consumer perception. Catherine Drewett, investigations manager at the ASA, stated that advertisers must consider the overall impression their campaigns create, noting that a medicine does not need to be named directly to be understood as a promotion for a prescription-only drug.
Alongside Voy’s sanctions, the watchdog issued bans against providers Juniper and MedExpress. A YouTube advertisement from Juniper proclaimed “The weight loss pill is here”, while an Instagram promotion by MedExpress invited users to “Join the waitlist” for “New weight loss tablets” using “No needles”. The enforcement action follows last month’s precedent when ads promoting unlicensed and prescription-only oral weight loss treatments became the first to be banned, including those by Simple Online Pharmacy and Pharmacy Online for social media pre-order waiting lists.
Regulators Back Rulings While Companies Defend Clinical Standards
The Medicines and Healthcare products Regulatory Agency (MHRA) backed the rulings. Julian Beach, executive director of operations at the MHRA, stated that prescription medicines are not consumer goods and that improper promotion poses serious public health risks. The ASA said it uses AI monitoring to keep the weight loss sector under ongoing review and would take action against ads that break the rules.
Dr Earim Chaudry, chief medical officer at Voy, stated that every patient decision at the company is clinician-led and that the campaigns were developed to align with existing standards. Voy cooperated fully with the regulator, withdrew the disputed advertisements while the investigation was underway, and confirmed it will not run them again. Meanwhile, a spokesperson for MedExpress told Chemist+Druggist that the advert was identified during a routine internal review and removed from all platforms before the company was contacted by the ASA.
Common Questions About Weight Loss Pill Advertising Rules
Why are oral weight loss pill ads banned in the UK?
UK advertising regulations strictly prohibit the promotion of prescription-only medicines directly to the public. Because GLP-1 oral weight loss tablets require a prescription, public-facing ads on buses, YouTube, and Instagram break the law.
Which companies faced ASA bans for weight loss advertising?
The ASA banned specific advertisements from Voy, Juniper, and MedExpress. These rulings follow earlier bans issued last month against Simple Online Pharmacy and Pharmacy Online for similar promotional practices.
Can supplements be mentioned in small print to bypass the rule?
No. The ASA ruled that small-print references to non-medicinal products like glucomannan do not change the overall impression of an ad if the primary imagery and wording promote prescription weight-loss treatments.
Worth a look